Although SGLT2 inhibitors and GLP-1RAs are expected to improve insulin resistance through weight reduction, TZDs directly target and specifically treat insulin resistance, which may lead to the superior effect of TZDs on endothelial function compared to SGLT2 and GLP1-RAs. Here, SLC5A2 is linked to Insulin resistance.